Naloxone Injection Recall Due to Manufacturing Process Deviations
Akorn, Inc. is recalling all lots of Naloxone Injection 0.4 mg/mL due to manufacturing process deviations. The manufacturer could not complete required stability studies.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 3/5 (High).
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is a risk-of-harm product (essential opioid overdose-reversal medication) where no illnesses or injuries have been reported but stability cannot be verified due to incomplete manufacturing studies.
Plain-English summary
Akorn, Inc. is recalling all lots of Naloxone Injection, USP 0.4 mg/mL in 1 mL vials. The product is distributed nationwide in the United States and Puerto Rico.
The recall is due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, the manufacturer went out of business and was unable to continue and complete stability studies required to verify the product's shelf life and efficacy.
The recalled product
- Product
- Naloxone Injection, USP 0.4 mg/mL, For Intravenous, Intramuscular or Subcutaneous Use, 1 mL vials, Rx only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045. ALL NDCs
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Injectable
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Part of a larger recall action
This product is one of 86 recalled by Akorn, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 86 products in this recall →Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · stability concern
See all →- ModeratePropranolol Hydrochloride 20 mg Tablets Recalled for Temperature Storage Deviations
FDA (Drugs) · 2024-01-03
- HighLow-dose aspirin recall due to improper storage temperature conditions
FDA (Drugs) · 2024-01-03
- HighEnoxaparin Sodium Injection recalled due to improper storage conditions
FDA (Drugs) · 2024-01-03
- HighOxcarbazepine Oral Suspension Recalled Due to Manufacturing and Stability Deviations
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Apraclonidine Ophthalmic Solution Due to Manufacturing Compliance Failures
FDA (Drugs) · 2023-06-07
Similar recalls
- ModerateOfloxacin Ophthalmic Solution Recalled Nationwide for Manufacturing Quality Issues
FDA (Drugs) · 2023-01-25
- ModerateAkorn Recalls Rifampin for Injection Due to Impurity Specification Failure
FDA (Drugs) · 2014-10-01
- HighAkorn Recalls Acetylcysteine for Injection Due to Manufacturing Deviations
FDA (Drugs) · 2018-07-18
- HighBetaxolol ophthalmic solution recalled for manufacturing process violations
FDA (Drugs) · 2023-01-25
- ModerateCiprofloxacin ophthalmic solution recalled for manufacturing practice deviations
FDA (Drugs) · 2023-01-25
- ModerateAkorn Recalls Moxifloxacin Ophthalmic Solution for CGMP Deviations
FDA (Drugs) · 2023-01-25